POST Online Media Lite Edition


NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (9.21.2021, 5:41pam CEST, WHO):   India 26,115    Brazil 9,458    United Kingdom 35,702    Russia 19,179    Turkey 27,688    Iran 17,397    Columbia 1,813    Italy 2,405    Indonesia 3,263    Germany 4,664    Mexico 4,983    South Africa 1,504    Philippines 18,937    Ukraine 5,159    Malaysia 14,345    Netherlands 1,370    Iraq 3,192    Japan 2,405    Bangladesh 1,562    Thailand 10,919    Pakistan 2,167    Romania 6,789    Morocco 2,246    Serbia 6,424    Jordan 1,075    Cuba 8,544    Nepal 1,036    Austria 1,162    Vietnam 8,681    Greece 2,124    Georgia 2,470    Belarus 1,941    Costa Rica 1,627    Bulgaria 2,360    Myanmar 1,687    Palestine 3,909    Croatia 1,037    Ireland 1,150    Libya 1,081    Lithuania 1,157    South Korea 1,729    Mongolia 2,543    Botswana 1,536    El Salvador 2,323    China 83    Singapore 0    New Zealand 15    Australia 1,515   

FDA system for treating pain without opioids

Staff Writer |
Boston Scientific Corp. (BSX) said that the U.S. Food and Drug Administration (FDA) has approved the Spectra WaveWriter Spinal Cord Stimulator or SCS System, which offers non-opioid treatment with multiple therapies for people with chronic pain.

Article continues below

According to the medical device maker, the SCS system is the first and only system approved by the FDA to simultaneously provide paresthesia-based and sub-perception therapy.

SCS is designed to deliver low electrical pulses of varying frequency, pulse width and amplitude, to the spinal cord to interrupt pain signals.

Paresthesia-based therapy provides pain relief with a light tingling sensation, while sub-perception therapy works without that sensation.

The system will enable physicians and patients to combine both therapies, customize therapy and deliver real-time feedback to treat chronic and debilitating pain successfully.

SCS was developed by Boston Scientific after more than a decade of clinical research focused on optimizing sub-perception and delivering multiple therapies intended for effective, long-term pain relief. These studies include the WHISPER study and the PROCO study.

The multi-center, prospective, double-blind, randomized PROCO study established in de novo patients that similar pain relief and improvement in quality of life measures are achieved independent of the type of frequency used in sub-perception SCS therapy when the proper target and dose are identified.

What to read next

U.S. hospitals vary nearly twofold in opioid prescribing rates
USA patients receive more pain medication, yet report worse pain
CDC issues tough new guidelines on use of prescription painkillers